Skip to main content
Year archive

BerGenBio — 2018 filings

All 100 regulatory filings released by BerGenBio (BGBIO) in 2018, sourced directly from the official regulator.

100 Filings
2018 Period
2018 filings (100)
Filing Released Lang
BerGenBio announces a change to its Board of Directors
Board/Management Information
2018-12-15 English
BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference
Investor Presentation
2018-12-12 English
Financial calendar
Report Publication Announcement
2018-12-11 English
BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH
Regulatory Filings
2018-12-03 English
BerGenBio to Present at the 3rd Nordic-American Life Science Conference in New York City November 29, 2018
Regulatory Filings
2018-11-29 English
BerGenBio appoints cancer drug development specialist Alan Barge MD as interim Chief Medical Officer
Board/Management Information
2018-11-21 English
BerGenBio ASA: Results for the Third Quarter 2018
Investor Presentation
2018-11-13 English
BerGenBio ASA: Results for the Third Quarter 2018
Interim / Quarterly Report Q3 2018
2018-11-13 English
BerGenBio ASA: Results for the Third Quarter 2018
Earnings Release Q3 2018
2018-11-13 English
BerGenBio ASA: Results for the Third Quarter 2018
Earnings Release Q3 2018
2018-11-13 English
BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC patients in bemcentinib + KEYTRUDA PhII combination trial
Regulatory Filings
2018-11-06 English
BerGenBio ASA: Invitation to Third Quarter 2018 Results Presentation and Webcast
Report Publication Announcement
2018-11-06 English
BerGenBio ASA: Share options to primary insiders
Remuneration Information
2018-11-05 English
BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA® in advanced NSCLC at SITC
Regulatory Filings
2018-11-02 English
BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor bemcentinib presented at ESMO
Regulatory Filings
2018-10-22 English
BerGenBio to present interim phase II clinical, preclinical and biomarker data with selective AXL inhibitor bemcentinib at ESMO
Regulatory Filings
2018-10-09 English
Shareholder disclosure
Major Shareholding Notification
2018-10-08 English
BerGenBio ASA (OSE:BGBIO): 5 October 2018 - Responsibility Statement for First Half 2018 report
Regulatory Filings H1 2018
2018-10-05 English
BerGenBio ASA (OSE:BGBIO): 5 October 2018 - Responsibility Statement for First Half 2018 report
Report Publication Announcement
2018-10-05 English
BerGenBio enters second stage of phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC
Investor Presentation
2018-10-05 English
BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes
Legal Proceedings Report
2018-09-25 English
BerGenBio ASA: Notice of Arbitration with Rigel Pharmaceuticals, Inc.
Legal Proceedings Report
2018-09-13 English
BerGenBio to present interim phase 2 clinical data with selective AXL inhibitor bemcentinib in non-small cell lung cancer at WCLC
Investor Presentation
2018-09-05 English
BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Investor Presentation
2018-08-30 English
BerGenBio ASA - Approval and publication of prospectus regarding listing of shares under the Share Option Programme
Report Publication Announcement
2018-08-29 English
BerGenBio ASA: Results for the Second Quarter and First Half 2018
Earnings Release H1 2018
2018-08-21 English
BerGenBio ASA: Results for the Second Quarter and First Half 2018
Interim / Quarterly Report H1 2018
2018-08-21 English
BerGenBio ASA: Results for the Second Quarter and First Half 2018
Investor Presentation
2018-08-21 English
BerGenBio ASA: Results for the Second Quarter and First Half 2018
Earnings Release H1 2018
2018-08-21 English
BerGenBio ASA: Invitation to Second Quarter and First Half 2018 Results Presentation and Webcast
Report Publication Announcement
2018-08-14 English
Selective AXL inhibitor bemcentinib meets pre-specified efficacy endpoint in stage 1 of NSCLC phase II combination trial with KEYTRUDA®
Regulatory Filings
2018-06-26 English
Selective AXL inhibitor bemcentinib meets pre-specified efficacy endpoint in stage 1 of NSCLC phase II combination trial with KEYTRUDA®
Earnings Release Q2 2018
2018-06-26 English
BerGenBio: Posters presented at Congress of European Hematology Association (EHA)
Legal Proceedings Report
2018-06-18 English
BerGenBio: Posters presented at Congress of European Hematology Association (EHA)
Regulatory Filings
2018-06-18 English
BerGenBio provides interim update on Phase II clinical programme with selective oral AXL inhibitor bemcentinib
Regulatory Filings
2018-06-03 English
BerGenBio ASA US CLINICAL TRIAL UPDATE
Regulatory Filings
2018-06-02 English
BerGenBio - Invitation to conference call: interim update on Ph II clinical programme with selective AXL inhibitor bemcentinib being presented at ASCO
Report Publication Announcement
2018-05-29 English
BerGenBio ASA: Share options to primary insiders
Share Issue/Capital Change
2018-05-23 English
BerGenBio to present interim clinical and biomarker data with selective AXL inhibitor bemcentinib in AML and MDS at EHA
Earnings Release Q2 2018
2018-05-18 English
BerGenBio to present interim clinical and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO
Regulatory Filings
2018-05-16 English
BerGenBio ASA: Results for the First Quarter 2018
Earnings Release Q1 2018
2018-05-15 English
BerGenBio ASA: Results for the First Quarter 2018
Investor Presentation Q1 2018
2018-05-15 English
BerGenBio ASA: Results for the First Quarter 2018
Interim / Quarterly Report Q1 2018
2018-05-15 English
BerGenBio ASA: Results for the First Quarter 2018
Earnings Release Q1 2018
2018-05-15 English
BerGenBio participation at upcoming healthcare investor and life sciences industry conferences
Report Publication Announcement
2018-05-14 English
BerGenBio ASA: Annual General Meeting
AGM Information
2018-05-14 Norwegian
BerGenBio ASA: Annual General Meeting
AGM Information
2018-05-14 English
BerGenBio ASA: Invitation to First Quarter 2018 Results Presentation and Webcast
Report Publication Announcement
2018-05-08 English
BerGenBio ASA (BGBIO): Notice of annual general meeting
AGM Information
2018-04-23 English
BerGenBio ASA (BGBIO): Notice of annual general meeting
AGM Information
2018-04-23 English
BerGenBio ASA (BGBIO): Notice of annual general meeting
AGM Information
2018-04-23 English
BerGenBio ASA (OSE:BGBIO): Annual report 2017
Investor Presentation
2018-04-23 English
BerGenBio ASA (OSE:BGBIO): Annual report 2017
Report Publication Announcement
2018-04-23 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2018-04-19 English
BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR
Regulatory Filings
2018-04-18 English
BerGenBio: Lovende data som viser selektiv AXL inhibitor bemcentinibs potensiale til å forbedre effekten av sjekkpunkthemmere ble presentert på AACR
Regulatory Filings
2018-04-18 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2018-04-13 English
Promising pre-clinical data supporting BerGenBio's pipeline to be published and presented at upcoming leading conferences
Investor Presentation
2018-04-13 English
Promising pre-clinical data supporting BerGenBio's pipeline to be published and presented at upcoming leading conferences
Regulatory Filings
2018-04-13 English
BerGenBio ASA announces successful NOK 187.5 million (USD 24 million) private placement of new shares
Capital/Financing Update
2018-04-13 Norwegian
BerGenBio ASA announces successful NOK 187.5 million (USD 24 million) private placement of new shares
Share Issue/Capital Change
2018-04-13 English
BerGenBio completes recruitment into first stage of Phase II NSCLC trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®
Legal Proceedings Report
2018-04-10 English
BerGenBio completes recruitment into first stage of Phase II NSCLC trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®
Regulatory Filings
2018-04-10 English
BerGenBio ASA: Board approval of 2017 annual financial statement
Report Publication Announcement
2018-04-05 English
BerGenBio ASA: Exercise of employee share options and increase of capital
Share Issue/Capital Change
2018-04-05 English
BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe
Regulatory Filings
2018-03-22 English
BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe
Regulatory Filings
2018-03-22 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2018-03-20 English
BerGenBio: Promising data highlighting bemcentinib's potential to improve efficacy of checkpoint inhibitors to be presented at AACR Annual Meeting
Regulatory Filings
2018-03-15 English
BerGenBio: Promising data highlighting bemcentinib's potential to improve efficacy of checkpoint inhibitors to be presented at AACR Annual Meeting
Regulatory Filings
2018-03-15 English
BerGenBio: Lovende data som viser bemcentinibs potensiale til å forbedre effekten av sjekkpunkthemmere presenteres på AACR's årsmøte
Regulatory Filings
2018-03-15 Norwegian
BerGenBio - US Clinical Trial Update
Legal Proceedings Report
2018-03-15 English
BerGenBio - US Clinical Trial Update
Regulatory Filings
2018-03-15 English
BerGenBio ASA: Extraordinary general meeting
AGM Information
2018-03-09 Norwegian
BerGenBio ASA: Extraordinary general meeting
AGM Information
2018-03-09 English
BerGenBio appoints Rune Skeie as Chief Financial Officer
Board/Management Information
2018-03-05 English
BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®
Regulatory Filings
2018-02-19 English
BerGenBio har fullført rekruttering av pasienter til første halvdel av Fase II-forsøket med bemcentinib i kombinasjon med KEYTRUDA® i brystkreft
Regulatory Filings
2018-02-19 Norwegian
BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®
Regulatory Filings
2018-02-19 English
BerGenBio har fullført rekruttering av pasienter til første halvdel av Fase II-forsøket med bemcentinib i kombinasjon med KEYTRUDA® i brystkreft
Investor Presentation
2018-02-19 Norwegian
BerGenBio ASA: Notice of extraordinary general meeting
AGM Information
2018-02-16 Norwegian
BerGenBio ASA: Notice of extraordinary general meeting
AGM Information
2018-02-16 English
BerGenBio ASA: Exercise of employee share options and increase of capital
Remuneration Information
2018-02-13 Norwegian
BerGenBio ASA: Exercise of employee share options and increase of capital
Share Issue/Capital Change
2018-02-13 English
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
Earnings Release FY 2017
2018-02-13 Norwegian
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
Investor Presentation
2018-02-13 Norwegian
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
Interim / Quarterly Report Q4 2017
2018-02-13 Norwegian
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
Earnings Release FY 2017
2018-02-13 English
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
Earnings Release Q4 2017
2018-02-13 Norwegian
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
Interim / Quarterly Report Q4 2017
2018-02-13 Norwegian
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
Investor Presentation
2018-02-13 Norwegian
Viktige milepæler nådd i 2017. Flere spennende testresultater ventes i 2018.
Earnings Release Q4 2017
2018-02-13 Norwegian
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast
Report Publication Announcement
2018-02-06 Norwegian
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast
Report Publication Announcement
2018-02-06 English
BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy
Regulatory Filings
2018-01-29 English
BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy
Earnings Release Q1 2018
2018-01-29 English
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 (bemcentinib) in NSCLC
Earnings Release Q1 2018
2018-01-09 English
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 (bemcentinib) in NSCLC
Earnings Release Q1 2018
2018-01-09 English
BerGenBio to present at Biotech Showcase 2018
Regulatory Filings
2018-01-08 English
BerGenBio to present at Biotech Showcase 2018
Regulatory Filings
2018-01-08 English